OraSure Technologies, Inc., a leader in point of care diagnostic tests and specimen collection and stabilization devices, and microbiome laboratory and analytical services, today announced that it has entered into a definitive agreement to acquire privately owned UrSure, Inc. for cash.
According to Dr. Adam Visconti, the CMO of the HIV/AIDS, Hepatitis, STD, and TB admin, “the tests led the clinical staff at the clinic to discuss adherence more routinely as a clinic, and made their approach to managing adherence more quantitative.”
UrSure, an HIV prevention company, today announced that the company has shipped the first order of their novel Point of Care PrEP adherence test to a domestic researcher.
Harvard spinoff has sold more than 4,000 tests to improve HIV care for vulnerable patients.
With the President's Advisory Council on HIV/AIDS meeting in Miami in October, Oakland Park's Midland Medical demonstrates promising results from innovative PrEP program.